Zosano Pharma — Ladenburg Thalmann 2015 Healthcare Conference
28 slides from Zosano Pharma's conference presentation, Sep 29, 2015

Slide 1: Corporate Presentation
Exhibit 99.1 Corporate Presentation Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015 Exhibit 99.1

Slide 2: Forward-Looking Statements
Forward-Looking This development further our candidates technologies “anticipate,” constitute to SEC incorrect. associated Although reflected assume 1circumstances differ expectations presentation onpossible no March materially in Actual we guarantees with obligation or forward-looking “design,” and

Slide 3: Zosano Pharma: Convenient and Easy-to-Use Drug Delivery System
Zosano Pharma 2Convenient and Drug Easy-to-Use Delivery System

Slide 4: Rapid Onset and High Bioavailability
Rapid Onset Zosano Hydrophilic 3Microneedles Pharma approach drug and areDrug High provides 200-350 formulation Delivery Bioavailability microns rapid coated System onset long on –tips close of microneedles proximity to capillary bed Formulation quickly dissolved by interstitial fluid for short Tmax

Slide 5: Zosano Formulations Demonstrated Higher Stability
100 Zosano Formulations Higher Dry, Packaging Demonstrated Phase 95 ZP-PTH Stable rity (%) H uP 085 hydrophilic T5 10 Forteo 80 90 4Storage215 product Pharma Zosano 320 (2-8 RT yr purged RT oC) Time Stable 2536 stability, Drug PTH formulation month with 35at40 (months) 30 Delivery Room nitrogen 40sh

Slide 6: Broad Technical Screening Across Molecule Types
Broad Technical Screening With Preclinical Daily es Glucagon LHRH Insulin Desmopressin lueBNP gol M Lar GRF Oligonucleotide Octreotide hGH Pentosan Undisclosed ecules Fentanyl Epinephrine VEGF Mol RWJ-445167 Small Lyme Diphtheria Influenza Zolmitriptan Vaccines Plasmid Rapid Tetanus therapeutic Week

Slide 7: Zosano Investment Highlights
Zosano Investment Differentiated Capable Fast Convenient Well ZP-Glucagon Weekly ZP-Triptan Robust 6Cashonset validated and IP Pharma ZP-PTH ofcash and with delivering (zolmitriptan) Highlights and for transdermal life equivalents pipeline short (ZSAN) easy-to-use: for severe cycle osteoporosis Tmax

Slide 8: Development Pipeline and Milestones
Development Preclinical ZP-Glucagon Severe Weekly Osteoporosis Start ZP-Triptan Migraine 7Data Milestone Completed Upcoming Legend: Multiple Undisclosed hypoglycemia ZP-PTH Upcoming Q4Phase Phase 15 H1 Pipeline Phase Phase 16 11 Phase Milestones 2 Oct 2 215Phase 3

Slide 9: ZP-Glucagon: Potential to Expand Severe Hypoglycemia Market
ZP-Glucagon Potential Severe Ease-of-use Underpenetrated Only Current Dry 8Efficient powder two hypoglycemia glucagon clinical to glucagon Expand critical needs for market development Severe injections toproducts for Highly be isthird-party life-threatening, reconstituted generates Hypoglycemia Unde

Slide 10: Current Treatment Complex, Zosano Solution Press-and-Apply
Treatment Current Complex, Significant Unstable Short Zosano Press-and-Apply 9Fast, simple, shelf Solution Products formulation multi-step Time life prep noafter prep Critical time pre-loaded Notreconstitution reconstitution, needed User-Friendly for Emergency disposable Stable,third drysystem Rescu

Slide 11: ZP-Glucagon Formulation Stability
100 Formulation Stability ZP-Glucagon 99 98 Purity % 096 95 10197 Demonstrated 5 6 Stability 7Patch 25CCCStability 2 3Formulation Months Formulation 4Formulation D a at 40C D Significant 25C 40C40° C over Competitive Six MonthsAdvantage

Slide 12: ZP-Glucagon Phase 1 PK Data
ZP-Glucagon Short 20 11 pg/ml subjects Tmax,tested High – Phase in Bioavailability, five-way 1 PK Data crossover vs. and Injection Low study Variability Across Doses

Slide 13: ZP-Glucagon PD Data
ZP-Glucagon PD Patch IM 12 mmol/l glucagon forD, C,All upper forearm abdomen Patch injection –arm Phase Doses1 Comparable Glucose Datatovs. Injection Injection

Slide 14: ZP-Glucagon Next Steps
ZP-Glucagon Next Launch Phase commenced Develop 13 Steps 1 Gen completed Genin 12for product Q1 product Severe 2015 Q1 using 2014; using Phase Hypoglycemia reusable received single-use 2 data expected applicator FDA applicator feedback October and regarding integrated 2015 Phase development patch 3

Slide 15: Weekly ZP-PTH: Differentiated from Forteo
Weekly Differentiated Forteo 20 Completed Demonstrated Efficacy 79% 66% Zosano Low 14 µgweekly fracture daily (PTH patch completed ZP-PTH of Weekly Daily weekly subcutaneous ZP-PTH 1-34) reduction technology Product 36 for month ZP-PTH ais dose ZP-PTH successful Osteoporosis only dose Profile with r

Slide 16: Daily ZP-PTH Phase 2 Trial Design
Daily 6Phase 165 comparator Ref: 15month post-menopausal Cosman, ZP-PTH 2 Trial multi-national Primary Design F., Patch et al. endpoint Program women J.trial Clin.with –Endocrin Increase low bone Metab, in spine density 95,151,2010 bone Daily density dose, Secondary patient self-administered endpoin

Slide 17: Daily ZP-PTH Pulsatile PK Achieved
Daily Pulsatile PK Achieved 16 OVER ZP-PTH Delivery dose TIMEPatch proportionate MEAN Critical Program AUC forand Anabolics –BY Phase pulsatile DOSE 2 PK pharmacokinetics Profile Variability in patch doses comparable to Forteo injectable

Slide 18: Daily ZP-PTH Higher BMD Gains
1.331% Daily Higher HIP Increase BMD 0.138% 0.553% BMD ZP-PTHZP-PTH (%) (0.634%) vs. SPINE 3.470% ZP- (0.330%) Placebo 2.960% 20µg All Ref: 17 Hip in Forteo BMD active Cosman 30µg 0.094% BMD Placebo ZP-PTH 95%etPatch 3.550% 4.970% CI 95% ZP-PTH treatments 40µg al Gains Program ZP-PTHvs. = ZP-PTH 20µ

Slide 19: Weekly PTH: Asahi's Phase 3 Data
Phase 3et Weekly Asahi’s Lower 2-year -79% Nakamura Fujita Watanabe, 18 rat dose 56.5mcg PTH Data al., study A. et28.2mcg Once al., Product for et.observed al, Once-Weekly Weekly weekly Weekly Carcinogenicity weekly Currently PTH no Injection carcinogenicity PTH reduced 56.5 Teriparatide Marketed re

Slide 20: Weekly ZP-PTH Phase 1 PK Profile
Weekly Eight-Way Robust Source: 19 ZP-PTH [add paper Patch Crossover citations] Program with – Phase 32 Patients 1 PK Demonstrated Profile Pulsatile PK & No Safety Concerns

Slide 21: Weekly ZP-PTH Phase 2 Development Plan
Phasepatch Objective: Study One Two Weekly Primary Secondary 20 patches 2design: ZP-PTH of Start endpoint: of Daily determine endpoint: of Weekly Expected 240 Weekly administration Patch total increase increase the ZP-PTH Program in patients ZP-PTH safety 1H in 2016 in spine 60 160 and randomized of

Slide 22: ZP-Triptan: Highly Suited for Acute Migraine
ZP-Triptan Highly Potential Comparable Self-administration US Multiple Phase Completed 21 $1.9 1Suited PK billion products best-in-class enrollment for and orfor Migraine better total safety Acute inprovides amigraine onset rapid large study inCondition Sepof and onset: data significant 2015 action

Slide 23: ZP-Triptan Rapid Onset of Action
222 Rapid ZP-Triptan Nasal Melt(1) Tmax Pain (H:MM) (Ave) (4) (5) (6) the Relief /(Ave)(5) Onset Products (1) (2) (3) Oral Tablets(2) hours(6) TmaxWith To Oral evaluated Nasal:Associated Average Average same be Included: Oral—Tablets: Potential Patch 63% atZecuity Imitrex Subcutaneous: achieved trip

Slide 24: ZP-Triptan Next Steps
ZP-Triptan Next Developing Enrollment Single Multiple Phase Expected Primary 23 Steps 1dose 2 data trial endpoint: patch tofor completed crossover product compare with expected Migraine doses 200 reduction using with three /patients Q4 Sep ascending 2015 zolmitriptan current 2015 ZP-Triptan inplanne

Slide 25: ZP-Patch Intellectual Property
724 ZP-Patch Patent Issued Transdermal Protection Patents US, Intellectual 321&& 3Mfg &Applicator 4Micro Patch Packaging Projection Retainer Ring (owned EU, PTH JP Until 52 Formulation/ JP Property 5Design& 2027 Delivery US, licensed) 4& EU, 3 JP Coating/PK/PD 3=US, Anchoring Control 22toUS, 12 2EU,

Slide 26: Financial Highlights
Financial in Revenue R&D G&A Net Shares 6/30/15 Cash Debt1 1. 2015 25 Cash millions loss IPO and $5.0 $1.8 $15.1 outstanding and 12/31/14 $7.6 $0.1 marketable Highlights and $11.0 $4.4 Q2cash $22.1 $14.2 $2.9 concurrent 2015 equivalents (basic FY securities1 2014 private andbalance, diluted)1 $50.6

Slide 27: Zosano Investment Highlights
Zosano Investment Differentiated Capable Fast Convenient Well ZP-Glucagon Weekly ZP-Triptan Robust Cash 26 onset validated and IP Pharma ZP-PTH ofcash and with delivering (zolmitriptan) Highlights and for transdermal life equivalents pipeline short (ZSAN) easy-to-use: for severe cycle osteoporosis T

Slide 28: Corporate Presentation
Corporate Presentation Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015
Source: SEC EDGAR · 8-K filed Sep 29, 2015
More decks from Zosano Pharma Corp
Investor Presentation (January 2022)44 slides · Jan 31, 2022
Investor Presentation (January 2021)37 slides · Jan 6, 2021
Investor Presentation (February 2020)35 slides · Feb 11, 2020
Investor Presentation (April 2016)49 slides · Apr 7, 2016
Investor Presentation (November 2015)28 slides · Nov 16, 2015
Investor Presentation (June 2015)27 slides · Jun 9, 2015